Abstract
The hottest ongoing debate in the interventional cardiology community has focused on the efficacy and safety of the 2 approved-for-marketing drug-eluting stent platforms: the sirolimus-eluting stent (SES) Cypher (Cordis Corporation, Miami, Florida) and the paclitaxel-eluting stent (PES) Taxus, (Boston Scientific Corporation, Natick, Massachusetts). The 2 devices significantly reduce the rate of recurrent stenoses and the need for repeat revascularization, including those in complex patients and lesion populations; the issue is whether there are clinical differences when comparing these stents in head-to-head trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
